|
TRDMT1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.10245146345278E-13 |
| Normal-vs-Stage2 |
2.20610000045696E-07 |
| Normal-vs-Stage3 |
3.77475828372553E-15 |
| Normal-vs-Stage4 |
7.86404275032737E-12 |
| Stage1-vs-Stage2 |
6.424000E-01 |
| Stage1-vs-Stage3 |
1.398630E-01 |
| Stage1-vs-Stage4 |
1.796390E-01 |
| Stage2-vs-Stage3 |
1.364980E-01 |
| Stage2-vs-Stage4 |
1.393800E-01 |
| Stage3-vs-Stage4 |
8.107000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
1.365100E-04 |
| Normal-vs-Asian |
3.14180004234998E-09 |
| Caucasian-vs-AfricanAmerican |
1.767780E-01 |
| Caucasian-vs-Asian |
7.505800E-01 |
| AfricanAmerican-vs-Asian |
3.170600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63091762317435E-13 |
| Normal-vs-Female |
1.62547753035369E-12 |
| Male-vs-Female |
6.585800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.94932958663685E-12 |
| Normal-vs-Age(41-60Yrs) |
3.96904731303493E-13 |
| Normal-vs-Age(61-80Yrs) |
4.57445192836303E-12 |
| Normal-vs-Age(81-100Yrs) |
1.13929999989715E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.967400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.516600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.081190E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.775800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.048400E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.229190E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.215700E-04 |
| Classical-VS-Follicular |
3.836200E-01 |
| Classical-VS-Other |
6.210600E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
2.177700E-03 |
| Tall-VS-Other |
3.337000E-01 |
| Tall-VS-Normal |
1.64646074551911E-12 |
| Follicular-VS-Other |
5.256000E-01 |
| Follicular-VS-Normal |
3.40739999993289E-07 |
| Other-VS-Normal |
9.036500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.99760216648792E-15 |
| Normal-vs-N1 |
4.92783591710122E-12 |
| N0-vs-N1 |
3.225600E-01 |
|
|
